Nektar Therapeutics (NKTR) Debt/Equity Ratio: History & Chart

Nektar Therapeutics(NKTR)

Biotechnology · San Francisco, CA

$40.00-2.22 (-5.26%)

Delayed quote: Oct 6, 2026, 2:30 PM EDT

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

San Francisco, CA

63 employees

www.nektar.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Howard W. Robin

View full financials

NKTR Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.15

DEBT TO EQUITY RATIO AVG TTM

-0.17

DEBT TO EQUITY RATIO AVG 3Y

1.18

DEBT TO EQUITY RATIO AVG 5Y

0.70

DEBT TO EQUITY RATIO AVG 10Y

0.77

DEBT TO EQUITY RATIO AVG 15Y

1.08

DEBT TO EQUITY RATIO AVG 20Y

1.33

CURRENT VS TTM AVG

+190.21%

CURRENT VS 3Y AVG

-87.25%

CURRENT VS 5Y AVG

-78.41%

CURRENT VS 10Y AVG

-80.41%

CURRENT VS 15Y AVG

-86.00%

CURRENT VS 20Y AVG

-88.67%

SECTOR MEDIAN · HEALTHCARE

0.11

median of 774 covered companies

CURRENT VS SECTOR MEDIAN

+36.83%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Nektar Therapeutics (NKTR)	$1.15B	0.15	-0.17	1.18	0.70
Amphastar Pharmaceuticals, Inc. (AMPH)vs ›	$1.14B	0.90	0.86	0.72	0.55
GoodRx Holdings, Inc. (GDRX)vs ›	$1.14B	0.83	0.81	0.86	0.88
Harrow Health, Inc. (HROW)vs ›	$1.14B	19.79	4.04	3.72	3.78
Avalyn Pharma Inc. Common Stock (AVLN)vs ›	$1.13B	0.04	N/A	N/A	N/A
Damora Therapeutics, Inc. (DMRA)vs ›	$1.18B	0.00	0.05	0.03	0.02
Replimune Group, Inc. (REPL)vs ›	$1.12B	1.06	0.43	0.29	0.22
First Tracks Biotherapeutics Inc (TRAX)vs ›	$1.11B	0.03	0.04	0.04	0.04
Tandem Diabetes Care, Inc. (TNDM)vs ›	$1.11B	5.67	2.33	1.73	1.38
STAAR Surgical Company (STAA)vs ›	$1.10B	0.10	0.11	0.10	0.10

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Nektar Therapeutics (NKTR)

$1.15B

0.15

-0.17

1.18

0.70

Amphastar Pharmaceuticals, Inc. (AMPH)vs ›

$1.14B

0.90

0.86

0.72

0.55

GoodRx Holdings, Inc. (GDRX)vs ›

$1.14B

0.83

0.81

0.86

0.88

Harrow Health, Inc. (HROW)vs ›

$1.14B

19.79

4.04

3.72

3.78

Avalyn Pharma Inc. Common Stock (AVLN)vs ›

$1.13B

0.04

N/A

Damora Therapeutics, Inc. (DMRA)vs ›

$1.18B

0.00

0.05

0.03

0.02

Replimune Group, Inc. (REPL)vs ›

$1.12B

1.06

0.43

0.29

0.22

First Tracks Biotherapeutics Inc (TRAX)vs ›

$1.11B

0.03

0.04

Tandem Diabetes Care, Inc. (TNDM)vs ›

$1.11B

5.67

2.33

1.73

1.38

STAAR Surgical Company (STAA)vs ›

$1.10B

0.10

0.11

0.10

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Nektar Therapeutics (NKTR)?

The debt to equity ratio for NKTR stock is 0.15.

Is Nektar Therapeutics's debt to equity ratio high or low?

The debt to equity ratio of 0.15 is 78% below its 5-year average of 0.70, around the middle of its 5-year range (-3.97–7.30).

What is the TTM average debt to equity ratio for Nektar Therapeutics (NKTR)?

The TTM average debt to equity ratio for NKTR stock is -0.17.

What is the 3Y average debt to equity ratio for Nektar Therapeutics (NKTR)?

The 3Y average debt to equity ratio for NKTR stock is 1.18.

What is the 5Y average debt to equity ratio for Nektar Therapeutics (NKTR)?

The 5Y average debt to equity ratio for NKTR stock is 0.70.

What is the 10Y average debt to equity ratio for Nektar Therapeutics (NKTR)?

The 10Y average debt to equity ratio for NKTR stock is 0.77.

What is the 15Y average debt to equity ratio for Nektar Therapeutics (NKTR)?

The 15Y average debt to equity ratio for NKTR stock is 1.08.

What is the 20Y average debt to equity ratio for Nektar Therapeutics (NKTR)?

The 20Y average debt to equity ratio for NKTR stock is 1.33.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.15
2026-03-31	0.25
2025-12-31	1.66
2025-09-30	1.08
2025-06-30	-3.97
2025-03-31	7.30
2024-12-31	1.69
2024-09-30	2.21
2024-06-30	2.76
2024-03-31	0.90
2023-12-31	0.90
2023-09-30	0.76
2023-06-30	0.63
2023-03-31	0.53
2022-12-31	0.36
2022-09-30	0.33
2022-06-30	0.30
2022-03-31	0.23
2021-12-31	0.21
2021-09-30	0.18
2021-06-30	0.16
2021-03-31	0.15
2020-12-31	0.14
2020-09-30	0.13
2020-06-30	0.12
2020-03-31	0.32
2019-12-31	0.29
2019-09-30	0.27
2019-06-30	0.22
2019-03-31	0.21
2018-12-31	0.14
2018-09-30	0.14
2018-06-30	0.13
2018-03-31	4.21
2017-12-31	2.79
2017-09-30	2.94
2017-06-30	73.27
2017-03-31	5.55
2016-12-31	2.82
2016-09-30	-3.65
2016-06-30	-6.34
2016-03-31	-909.95
2015-12-31	38.57
2015-09-30	3.39
2015-06-30	3.80
2015-03-31	1.74
2014-12-31	3.68
2014-09-30	2.76
2014-06-30	-3.71
2014-03-31	-13.46
2013-12-31	-1.52
2013-09-30	-2.67
2013-06-30	-3.33
2013-03-31	-51.82
2012-12-31	2.91
2012-09-30	1.44
2012-06-30	1.72
2012-03-31	1.41
2011-12-31	1.16
2011-09-30	1.00
2011-06-30	0.92
2011-03-31	0.82
2010-12-31	2.56
2010-09-30	2.17
2010-06-30	2.13
2010-03-31	2.23
2009-12-31	2.28
2009-09-30	2.21
2009-06-30	1.80
2009-03-31	1.48
2008-12-31	1.24
2008-09-30	3.10
2008-06-30	2.35
2008-03-31	1.93
2007-12-31	1.58
2007-09-30	2.37
2007-06-30	2.13
2007-03-31	1.91
2006-12-31	1.93
2006-09-30	1.74
2006-06-30	1.65
2006-03-31	1.43
2005-12-31	1.34
2005-09-30	1.01
2005-06-30	0.46
2005-03-31	0.44
2004-12-31	0.43
2004-09-30	0.42
2004-06-30	0.41
2004-03-31	0.42
2003-12-31	2.40
2003-09-30	2.68
2003-06-30	2.35
2003-03-31	1.77
2002-12-31	1.61
2002-09-30	1.40

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.15

2026-03-31

0.25

2025-12-31

1.66

2025-09-30

1.08

2025-06-30

-3.97

2025-03-31

7.30

2024-12-31

1.69

2024-09-30

2.21

2024-06-30

2.76

2024-03-31

0.90

2023-12-31

0.90

2023-09-30

0.76

2023-06-30

0.63

2023-03-31

0.53

2022-12-31

0.36

2022-09-30

0.33

2022-06-30

0.30

2022-03-31

0.23

2021-12-31

0.21

2021-09-30

0.18

2021-06-30

0.16

2021-03-31

0.15

2020-12-31

0.14

2020-09-30

0.13

2020-06-30

0.12

2020-03-31

0.32

2019-12-31

0.29

2019-09-30

0.27

2019-06-30

0.22

2019-03-31

0.21

2018-12-31

0.14

2018-09-30

0.14

2018-06-30

0.13

2018-03-31

4.21

2017-12-31

2.79

2017-09-30

2.94

2017-06-30

73.27

2017-03-31

5.55

2016-12-31

2.82

2016-09-30

-3.65

2016-06-30

-6.34

2016-03-31

-909.95

2015-12-31

38.57

2015-09-30

3.39

2015-06-30

3.80

2015-03-31

1.74

2014-12-31

3.68

2014-09-30

2.76

2014-06-30

-3.71

2014-03-31

-13.46

2013-12-31

-1.52

2013-09-30

-2.67

2013-06-30

-3.33

2013-03-31

-51.82

2012-12-31

2.91

2012-09-30

1.44

2012-06-30

1.72

2012-03-31

1.41

2011-12-31

1.16

2011-09-30

1.00

2011-06-30

0.92

2011-03-31

0.82

2010-12-31

2.56

2010-09-30

2.17

2010-06-30

2.13

2010-03-31

2.23

2009-12-31

2.28

2009-09-30

2.21

2009-06-30

1.80

2009-03-31

1.48

2008-12-31

1.24

2008-09-30

3.10

2008-06-30

2.35

2008-03-31

1.93

2007-12-31

1.58

2007-09-30

2.37

2007-06-30

2.13

2007-03-31

1.91

2006-12-31

1.93

2006-09-30

1.74

2006-06-30

1.65

2006-03-31

1.43

2005-12-31

1.34

2005-09-30

1.01

2005-06-30

0.46

2005-03-31

0.44

2004-12-31

0.43

2004-09-30

0.42

2004-06-30

0.41

2004-03-31

0.42

2003-12-31

2.40

2003-09-30

2.68

2003-06-30

2.35

2003-03-31

1.77

2002-12-31

1.61

2002-09-30

1.40

Debt to Equity Ratio: 0.15

NKTR Debt to Equity Ratio

NKTR Average Debt to Equity Ratio Chart

NKTR Current vs Average Debt to Equity Ratio Chart

NKTR Debt to Equity Ratio Metrics

NKTR Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

NKTR Debt to Equity Ratio History

Related Metrics